Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

AHCO vs BBNX: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

AHCO Wins Head-to-Head Institutional Verdict (6–0 across 6 Pillars · 7–3 Matrix Metrics)

AHCO Overall Winner 6-Pillar Tally: AHCO 6 – 0 BBNX Matrix Metrics: AHCO 7 – 3 BBNX

As of Nov 20, 2026, AdaptHealth Corp. (AHCO) is the stronger overall head-to-head candidate over Beta Bionics, Inc. (BBNX) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). AHCO carries a Unified Composite Score of 45.2/100 (HOLD) at $7.20 (7.8x Forward P/E, 3.8% operating margin), whereas BBNX carries 52.1/100 (HOLD) at $13.36 (N/M Forward P/E, -72.8% operating margin).

  • Composite vs. Pillar Nuance: While BBNX currently prints a higher short-term Unified Composite Score (52.1/100 HOLD vs. AHCO 45.2/100 HOLD), AHCO captures the overall institutional head-to-head verdict (7–3 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (3.8% vs. -72.8% operating margin) and revenue trajectory (+10.9% vs. +30.3% YoY).
  • Technical & Structure Timing Caution: AHCO trades in a Markup technical trend (SURGE options phase, RSI 57.1); meanwhile BBNX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 35.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About AHCO vs BBNX
AHCO NASDAQ Head-to-Head Winner
AdaptHealth Corp. Common Stock
Services-Home Health Care Services
$7.20
-0.69% 1D
Market Cap $989.8M
TTM Revenue $3.44B
Forward P/E 7.8x
Beta / 30D Vol 0.17β · 67% Vol
Unified Composite Score
45.2 / 100 HOLD
Tech 29.0 Fund 46.0 Flow 54.0 Mom 60.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (7.8% over 20 days), RSI 57
RSI-14: 57.1 · SMA20: $6.96 · SMA50: $6.32
BBNX NASDAQ
Beta Bionics, Inc. Common Stock
Surgical & Medical Instruments & Apparatus
$13.36
+0.3% 1D
Market Cap $724.2M
TTM Revenue $127M
Forward P/E N/M
Beta / 30D Vol 1.75β · 104% Vol
Unified Composite Score
52.1 / 100 HOLD
Tech 50.0 Fund 53.0 Flow 69.0 Mom 68.9
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -5.2%), weak momentum, RSI 35
RSI-14: 35.1 · SMA20: $16.42 · SMA50: $18.10

6-Pillar Scorecard Institutional Category Breakdown (AHCO 6 – 0 BBNX)

Columns: Metric · AHCO · BBNX
1. Valuation Multiples AHCO
Forward P/E 7.8x N/M
Trailing P/E 7.8x N/M
PEG Ratio N/M N/M
EV / Revenue 0.9x 5.1x
2. Growth & Scale AHCO
Revenue Growth (YoY) +10.9% +30.3%
Earnings Growth (YoY) +6.7% +0.0%
TTM Revenue (USD) $3.44B $127M
Market Cap $989.8M $724.2M
3. Profitability & Quality AHCO
Gross Margin 18.2% 58.6%
Operating Margin 3.8% -72.8%
Net Profit Margin -11.8% -65.3%
Return on Equity (ROE) -28.4% -23.9%
4. Balance Sheet & Cash Flow AHCO
Cash Generation (TTM) $82M -$66M
Cash Flow Margin 2.4% -51.8%
Net Cash / Leverage $1.97B Net Debt (1.67x D/E) $75M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning AHCO
Options Structure Phase SURGE CONSOLIDATION
Current IV / %ile 66.9% (12th %ile) 0.0% (<1st %ile)
Put/Call OI Skew N/A 0.01x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markup DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat AHCO
OpEx & R&D Intensity 14.4% of Rev ($495M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Devices Operator Medical Devices Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: AHCO (7) vs BBNX (3)
Institutional Metric AHCO BBNX Criterion Row Edge
Market Capitalization
Scale
$989.8M $724.2M Larger Scale AHCO
Trailing P/E Ratio
Valuation
7.8x N/M Lower Multiple AHCO
Forward P/E Ratio
Valuation
7.8x N/M Lower Multiple AHCO
Revenue Growth (YoY)
Growth
+10.9% +30.3% Higher Growth BBNX
Operating Margin (TTM)
Profitability
3.8% -72.8% Higher Margin AHCO
Net Profit Margin
Profitability
-11.8% -65.3% Higher Margin AHCO
Return on Equity (ROE)
Capital Efficiency
-28.4% -23.9% Higher ROE BBNX
52-Week Range Position
Momentum
24% ($5–$13) 19% ($9–$33) Stronger Trend AHCO
Beta / 30D Volatility
Risk Regime
0.17β · 67% Vol 1.75β · 104% Vol Lower Realized Risk AHCO
Unified Institutional Score
Composite Signal
45.2 / 100 (HOLD) 52.1 / 100 (HOLD) Higher Composite BBNX
Trailing 12M Revenue (USD)
Operating Scale
$3.44B $127M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
18.2% 58.6% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 0.9x EV/Rev N/M PEG · 5.1x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$82M ($1.97B Net Debt (1.67x D/E)) -$66M ($75M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon AHCO +47.61 pp
AHCO: +16.69% · BBNX: -30.92%
3M Horizon AHCO +60.18 pp
AHCO: +27.89% · BBNX: -32.29%
6M Horizon BBNX +44.13 pp
AHCO: -31.1% · BBNX: +13.03%
1Y Horizon AHCO +30.92 pp
AHCO: -20.88% · BBNX: -51.8%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period AHCO Revenue BBNX Revenue AHCO Op. Margin BBNX Op. Margin Margin Leader
FY2018 $350M N/A 9.0% N/A AHCO
FY2019 $530M N/A 5.5% N/A AHCO
FY2020 $1.06B N/A 6.8% N/A AHCO
FY2021 $2.45B N/A 9.2% N/A AHCO
FY2022 $2.97B N/A 6.4% N/A AHCO
FY2023 $3.20B $10M -18.7% -298.9% AHCO
FY2024 $3.26B $70M 8.1% -69.5% AHCO
FY2025 $3.24B $100M 2.8% -71.5% AHCO

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
AHCO SURGE
6d in phase · OBV NEUTRAL
Current IV 66.9%
IV Percentile 12th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact AHCO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
BBNX CONSOLIDATION
88d in phase · OBV DISTRIBUTION
Current IV 0.0%
IV Percentile <1st %ile
Put/Call OI Skew 0.01x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact BBNX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
AHCO Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $989.8M market capitalization and 3.8% operating margin.
OpEx & R&D Reinvestment 14.4% of Rev ($495M)
90D Engineering Disclosures 0 Published
BBNX Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $724.2M market capitalization and -72.8% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ AHCO vs BBNX Key Questions & Quantitative Answers

As of Nov 20, 2026, AdaptHealth Corp. (AHCO) is the stronger overall head-to-head candidate over Beta Bionics, Inc. (BBNX) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). AHCO carries a Unified Composite Score of 45.2/100 (HOLD) at $7.20 (7.8x Forward P/E, 3.8% operating margin), whereas BBNX carries 52.1/100 (HOLD) at $13.36 (N/M Forward P/E, -72.8% operating margin). Composite vs. Pillar Nuance: While BBNX currently prints a higher short-term Unified Composite Score (52.1/100 HOLD vs. AHCO 45.2/100 HOLD), AHCO captures the overall institutional head-to-head verdict (7–3 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (3.8% vs. -72.8% operating margin) and revenue trajectory (+10.9% vs. +30.3% YoY). Technical & Structure Timing Caution: AHCO trades in a Markup technical trend (SURGE options phase, RSI 57.1); meanwhile BBNX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 35.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

AHCO leads the Growth & Scale pillar: AHCO posts +10.9% YoY revenue growth and +6.7% YoY earnings growth on $3.44B TTM revenue (18.2% gross margin, 3.8% operating margin), compared with BBNX at +30.3% YoY revenue growth and +0.0% YoY earnings growth on $127M TTM revenue (58.6% gross margin, -72.8% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), AHCO cumulative revenue shifted +825.7% while BBNX shifted +900.0%. In operating R&D and SG&A reinvestment, AHCO deploys 14.4% of Rev ($495M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for BBNX.

AHCO screens cheaper on headline valuation multiples. AHCO trades at 7.8x Forward P/E, 7.8x Trailing P/E, N/M PEG, and 0.9x EV/Revenue (2.4% FCF margin), whereas BBNX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 5.1x EV/Revenue (-51.8% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against AHCO (-28.4% ROE) versus BBNX (-23.9% ROE) capital efficiency.

In options market volatility and institutional positioning, AHCO carries 66.9% implied volatility (12th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a SURGE options structure phase (0.17β · 67% Vol realized risk). By comparison, BBNX carries 0.0% implied volatility (<1st %ile, Compressed (<25th %ile)), a 0.01x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.75β · 104% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.